The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Role of Neuregulin-1/ErbB Signaling in Cardiovascular Physiology and Disease: Implications for Therapy of Heart Failure
Open accessAbstract
Since the discovery that neuregulin-1 (NRG-1)/ErbB signaling is indispensable in cardiac development, evidence has shown that this system also plays a crucial role in the adult heart. In patients, an inhibitory ErbB2 antibody, trastuzumab, used in the treatment of mammary carcinomas, increases the risk for the development of cardiotoxic cardiomyopathy. Postnatal disruption of NRG-1/ErbB signaling by gene targeting in mice leads to dilated cardiomyopathy. Initially, the search for the mechanisms behind these observations focused mainly on the effects of NRG-1 on cardiomyocyte growth and survival and revealed that NRG-1 has Akt-dependent antiapoptotic effects in cultured cardiomyocytes. In vivo studies, however, did not uniformly reinforce a role for apoptosis in the development of cardiomyopathy induced by impaired NRG-1/ErbB signaling. More recent studies have revealed that NRG-1 is involved in the regulation of cardiac sympathovagal balances by counterbalancing adrenergic stimulation of the adult myocardium and through an obligatory interaction with the muscarinic cholinergic system. NRG-1 is synthesized and released by the endocardial and cardiac microvascular endothelium, dynamically controlled by neurohormonal and biomechanical stimuli. The physiology of the cardiac NRG-1/ErbB system has implications for the treatment of both cancer and heart failure. Clinical studies in breast cancer with novel ErbB inhibitors are currently underway. Novel oncological indications for ErbB inhibition are emerging; cardiovascular side effects need to be carefully monitored. On the other hand, pharmacological activation of ErbB signaling is likely an unrecognized and beneficial effect of currently used drugs in heart failure and a promising therapeutic approach to prevent or reverse myocardial dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1215 · Cited by 1,563
Requirement for neuregulin receptor erbB2 in neural and cardiac development
Lee, K.-F., Simon, H., Chen, H., Bates, B., Hung, M.-C., & Hauser, C. (1995) · Nature · doi:10.1038/378394a0 · Cited by 1,290
Multiple essential functions of neuregulin in development
Meyer, D., & Birchmeier, C. (1995) · Nature · doi:10.1038/378386a0 · Cited by 1,262
Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor
Gassmann, M., Casagranda, F., Orioli, D., Simon, H., Lai, C., Klein, R., & Lemke, G. (1995) · Nature · doi:10.1038/378390a0 · Cited by 1,148
Neuregulins: functions, forms, and signaling strategies
Falls, D. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00102-7 · Cited by 1,071
The biology of erbB-2/nue/HER-2 and its role in cancer
Hynes, N. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90012-4 · Cited by 971
Identification of Heregulin, a Specific Activator of p185 erbB2
Holmes, W. E., Sliwkowski, M. X., Akita, R. W., Henzel, W. J., Lee, J., Park, J. W., Yansura, D., Abadi, N., Raab, H., Lewis, G. D., et al. (1992) · Science · doi:10.1126/science.256.5060.1205 · Cited by 962
ErbB2 is essential in the prevention of dilated cardiomyopathy
Crone, S. A., Zhao, Y.-Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., Peterson, K. L., Chen, J., Kahn, R., Condorelli, G., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-459 · Cited by 903
Cited by
Physiological and pathological cardiac hypertrophy
Shimizu, I., & Minamino, T. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.06.001 · Cited by 887
Cancer drugs and the heart: importance and management
Suter, T. M., & Ewer, M. S. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs181 · Cited by 472
Evaluation and Management of Patients With Heart Disease and Cancer: Cardio-Oncology
Herrmann, J., Lerman, A., Sandhu, N. P., Villarraga, H. R., Mulvagh, S. L., & Kohli, M. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.05.013 · Cited by 422
Pituskin, E., Mackey, J. R., Koshman, S., Jassal, D., Pitz, M., Haykowsky, M. J., Pagano, J. J., Chow, K., Thompson, R. B., Vos, L. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.7830 · Cited by 408
Vascular Toxicities of Cancer Therapies: The Old and the New – An Evolving Avenue
Herrmann, J., Yang, E. H., Iliescu, C. A., Cilingiroglu, M., Charitakis, K., Hakeem, A., Toutouzas, K., Leesar, M. A., Grines, C. L., & Marmagkiolis, K. (2016) · Circulation · doi:10.1161/circulationaha.115.018347 · Cited by 329
Expression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease
Chen, J., Zeng, F., Forrester, S. J., Eguchi, S., Zhang, M.-Z., & Harris, R. C. (2016) · Physiological Reviews · doi:10.1152/physrev.00030.2015 · Cited by 327
Cell Communications in the Heart
Tirziu, D., Giordano, F. J., & Simons, M. (2010) · Circulation · doi:10.1161/circulationaha.108.847731 · Cited by 303
Novel biomarkers for cardiovascular risk prediction.
Wang, J., Tan, G.-J., Han, L.-N., Bai, Y., He, M., & Liu, H. (2017) · PubMed · doi:10.11909/j.issn.1671-5411.2017.02.008 · Cited by 256
Kitani, T., Ong, S.-G., Lam, C. K., Rhee, J.-W., Zhang, J. Z., Oikonomopoulos, A., Ma, N., Tian, L., Lee, J., Telli, M. L., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037357 · Cited by 200
Cardiac Nonmyocytes in the Hub of Cardiac Hypertrophy
Kamo, T., Akazawa, H., & Komuro, I. (2015) · Circulation Research · doi:10.1161/circresaha.117.305349 · Cited by 171
Cardiokines: recent progress in elucidating the cardiac secretome
Shimano, M., Ouchi, N., & Walsh, K. (2012) · Circulation · doi:10.1161/circulationaha.112.150656 · Cited by 116
CellO: comprehensive and hierarchical cell type classification of human cells with the Cell Ontology
Bernstein, M. N., Ma, Z., Gleicher, M., & Dewey, C. N. (2021) · iScience · doi:10.1016/j.isci.2020.101913 · Cited by 45
Metadata
- Authors
- Lemmens, K., Doggen, K., & De Keulenaer, G. W.
- Venue
- Circulation
- Published
- 2007-08-21
- Volume
- 116
- Issue
- 8
- Pages
- 954-960
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2045570557
- Cited by
- 286
- References
- 48
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.